You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023138010
Dec 202383011
Jan 20242601
Feb 20242206
Mar 20241605
Apr 20241006
May 20241802
Jun 20241200
Jul 20243604
Aug 20241204
Sep 20242405
Oct 20243409
Nov 20242405
Dec 20241806
Jan 20253604
Feb 2025204
Mar 2025207
Apr 20251012
May 2025007
Jun 2025005
Total5140113